This case raises multiple lingering questions regarding the management of patients with mucinous ovarian carcinoma, including the role of HER2-targeted therapy in the treatment of advanced stage disease, the ideal management and prognostication of patients with stage IC disease, and the genetic and environmental risk factors specific to mucinous ovarian tumors. This evidence concerns the gene ERBB2 and ovarian mucinous neoplasm.